ZTS
NYSE · Pharmaceuticals
Zoetis Inc
$76.68
+2.29 (+3.07%)
Financial Highlights (FY 2026)
Revenue
8.84B
Net Income
2.50B
Gross Margin
71.9%
Profit Margin
28.2%
Rev Growth
+5.4%
D/E Ratio
2.72
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 71.9% | 71.9% | 28.1% | 28.1% |
| Operating Margin | 35.5% | 31.9% | 32.3% | 33.9% |
| Profit Margin | 28.2% | 26.8% | 25.1% | 28.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 8.84B | 8.38B | 12.02B | 10.95B |
| Gross Profit | 6.36B | 6.03B | 3.38B | 3.08B |
| Operating Income | 3.14B | 2.68B | 3.88B | 3.71B |
| Net Income | 2.50B | 2.13B | 3.02B | 3.10B |
| Gross Margin | 71.9% | 71.9% | 28.1% | 28.1% |
| Operating Margin | 35.5% | 31.9% | 32.3% | 33.9% |
| Profit Margin | 28.2% | 26.8% | 25.1% | 28.3% |
| Rev Growth | +5.4% | +5.4% | +1.9% | +24.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 11.70B | 11.70B | 18.38B | 22.65B |
| Total Equity | 4.31B | 4.31B | 33.02B | 33.90B |
| D/E Ratio | 2.72 | 2.72 | 0.56 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 3.26B | 2.93B | 4.97B | 3.99B |
| Free Cash Flow | — | — | 2.28B | 2.09B |